Cargando…

Varying outcomes of triple-negative breast cancer in different age groups–prognostic value of clinical features and proliferation

PURPOSE: Triple-negative breast cancer (TNBC) is an aggressive disease lacking specific biomarkers to guide treatment decisions. We evaluated the combined prognostic impact of clinical features and novel biomarkers of cell cycle-progression in age-dependent subgroups of TNBC patients. METHODS: One h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vihervuori, H., Korpinen, K., Autere, T. A., Repo, H., Talvinen, K., Kronqvist, P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Preclinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633490/ https://www.ncbi.nlm.nih.gov/pubmed/36261751 http://dx.doi.org/10.1007/s10549-022-06767-1

Ejemplares similares

Tumor-infiltrating lymphocytes and CD8(+) T cells predict survival of triple-negative breast cancer
por: Vihervuori, H., et al.
Publicado: (2019)

Endocan as a prognostic biomarker of triple-negative breast cancer
por: Sagara, Atsunobu, et al.
Publicado: (2016)

T-bet(+) lymphocytes infiltration as an independent better prognostic indicator for triple-negative breast cancer
por: Mori, Hitomi, et al.
Publicado: (2019)

A prognostic model based on cell-cycle control predicts outcome of breast cancer patients
por: Repo, Heli, et al.
Publicado: (2020)

Circulating tumor cells in non-metastatic triple-negative breast cancer
por: Karhade, Mandar, et al.
Publicado: (2014)

Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies
por: Hida, Akira I., et al.
Publicado: (2016)

Prognostic value of tumor–stroma ratio combined with the immune status of tumors in invasive breast carcinoma
por: Vangangelt, K. M. H., et al.
Publicado: (2017)

Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer
por: Thakkar, A., et al.
Publicado: (2016)

MCP-1 is overexpressed in triple-negative breast cancers and drives cancer invasiveness and metastasis
por: Dutta, Pranabananda, et al.
Publicado: (2018)

pHLIP(Var7)-P1AP suppresses tumor cell proliferation in MDA-MB-231 triple-negative breast cancer by targeting protease activated receptor 1
por: Yu, MingMing, et al.
Publicado: (2020)

The PDGF pathway in breast cancer is linked to tumour aggressiveness, triple-negative subtype and early recurrence
por: Jansson, Sara, et al.
Publicado: (2018)

A comparison of the molecular subtypes of triple-negative breast cancer among non-Asian and Taiwanese women
por: Tseng, Ling-Ming, et al.
Publicado: (2017)

Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer
por: He, Jichao, et al.
Publicado: (2019)

Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy
por: Girgert, Rainer, et al.
Publicado: (2012)

Expression of melatonin receptors in triple negative breast cancer (TNBC) in African American and Caucasian women: relation to survival
por: Oprea-Ilies, Gabriela, et al.
Publicado: (2012)

Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors
por: Grenader, Tal, et al.
Publicado: (2020)

MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975
por: Tang, Minhong, et al.
Publicado: (2022)

Gene expression analysis to detect disseminated tumor cells in the bone marrow of triple-negative breast cancer patients predicts metastatic relapse
por: Siddappa, Chidananda M., et al.
Publicado: (2019)

Integrative prognostic analysis of tumor–infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy
por: Yazaki, Shu, et al.
Publicado: (2022)

DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy
por: Bernier, Cynthia, et al.
Publicado: (2018)

Nonphosphorylatable PEA15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of IL-8 expression
por: Park, Jihyun, et al.
Publicado: (2021)

Proliferation marker securin identifies favourable outcome in invasive ductal breast cancer
por: Talvinen, K, et al.
Publicado: (2008)

Downregulation of miR-205 contributes to epithelial–mesenchymal transition and invasion in triple-negative breast cancer by targeting HMGB1–RAGE signaling pathway
por: Wang, Ling, et al.
Publicado: (2019)

Prognostic value of LINE-1 retrotransposon expression and its subcellular localization in breast cancer
por: Chen, Long, et al.
Publicado: (2012)

The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis
por: Engels, C. C., et al.
Publicado: (2015)

Molecular features of androgen-receptor low, estrogen receptor-negative breast cancers in the Carolina breast cancer study
por: Jinna, Nikita D., et al.
Publicado: (2023)

MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer
por: Han, Jinil, et al.
Publicado: (2017)

Simvastatin treatment varies the radiation response of human breast cells in 2D or 3D culture
por: Manda, Katrin, et al.
Publicado: (2020)

Formin Proteins FHOD1 and INF2 in Triple-Negative Breast Cancer: Association With Basal Markers and Functional Activities
por: Heuser, Vanina D, et al.
Publicado: (2018)

The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast
por: Narbe, Ulrik, et al.
Publicado: (2019)

Clinicopathological and prognostic significance of mitogen-activated protein kinases (MAPK) in breast cancers
por: Ahmad, Dena A. J., et al.
Publicado: (2016)

Securin promotes the identification of favourable outcome in invasive breast cancer
por: Talvinen, K, et al.
Publicado: (2009)

PTTG1-interacting protein (PTTG1IP/PBF) predicts breast cancer survival
por: Repo, Heli, et al.
Publicado: (2017)

Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion
por: Mazumdar, Abhijit, et al.
Publicado: (2016)

Prognostic values of EDNRB in triple-negative breast cancer
por: Liu, Shaoqing, et al.
Publicado: (2020)

Novel Multiomics Profiling of Human Carotid Atherosclerotic Plaques and Plasma Reveals Biliverdin Reductase B as a Marker of Intraplaque Hemorrhage
por: Matic, Ljubica Perisic, et al.
Publicado: (2018)

Digital image analysis of Ki67 proliferation index in breast cancer using virtual dual staining on whole tissue sections: clinical validation and inter-platform agreement
por: Koopman, Timco, et al.
Publicado: (2018)

MRPS23 amplification and gene expression in breast cancer; association with proliferation and the non-basal subtypes
por: Klæstad, Elise, et al.
Publicado: (2020)

Histone methyltransferases regulate the transcriptional expression of ERα and the proliferation of tamoxifen-resistant breast cancer cells
por: Kim, Seung-Su, et al.
Publicado: (2020)

A novel bis-aryl urea compound inhibits tumor proliferation via cathepsin D-associated apoptosis
por: Wu, Jianping, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fvblppu9st1r3hcs9ct0ooag9s